Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split
at www.tipranks.com (Fri, 24-Jul 5:18 PM)
Liminatus Pharma’s Proposed $320M Merger with InnocsAI Signals Bold Expansion Into Cell Therapy Pipeline
Market Chameleon (Thu, 21-May 9:52 AM)
